Lipocine Inc. updates and files new corporate investor presentation

Rhea-AI Filing Summary

Lipocine Inc. (LPCN) filed a current report to announce that it has updated the corporate presentation it uses in meetings with investors, analysts and other stakeholders. The updated materials are being made publicly available as Exhibit 99.1 to this report. By filing the presentation, the company is providing broader market access to the same information it shares in its investor meetings.

false 0001535955 0001535955 2025-11-18 2025-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

November 18, 2025

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware		99-0370688
(State or other jurisdiction of incorporation)		(IRS Employer Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed with this report:

Exhibit No.		Description
99.1		Corporate Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			LIPOCINE INC.
Date:	November 18, 2025		By:	/s/ Mahesh V. Patel
				Mahesh V. Patel
				President and Chief Executive Officer

FAQ

What did Lipocine Inc. (LPCN) announce in this Form 8-K?

Lipocine Inc. reported that it has updated the corporate presentation it uses with investors, analysts and others, and has filed the updated presentation as Exhibit 99.1.

What is included as Exhibit 99.1 in Lipocine's 8-K filing?

Exhibit 99.1 is Lipocine’s updated corporate presentation, which summarizes information the company shares in meetings with investors, analysts and other interested parties.

Does this Lipocine (LPCN) 8-K report any new financial results or major transactions?

No. This report focuses on the filing of an updated corporate presentation as Exhibit 99.1; it does not describe new financial results or major transactions.

Why does Lipocine file its corporate presentation with the SEC?

By filing the presentation as Exhibit 99.1, Lipocine makes its investor presentation publicly available to all market participants, aligning the information shared in investor meetings with public disclosures.

Who signed the Lipocine (LPCN) Form 8-K for the updated presentation?

The report was signed on behalf of Lipocine Inc. by Mahesh V. Patel, the company’s President and Chief Executive Officer.

Which exchange lists Lipocine Inc. common stock and under what symbol?

Lipocine Inc.’s common stock, par value $0.0001 per share, is listed on The NASDAQ Stock Market LLC under the trading symbol LPCN.